Dry AMD is one of the two forms of the ocular disease that ranks as the leading cause of blindness in adults over age 65, driven by the slow loss of photoreceptor cells over time. Dry AMD begins ...

There are two main types: dry (atrophic) AMD and wet (neovascular) AMD. Dry AMD is more common, accounting for about 80–90% of cases. It occurs when the macula, the part of the retina ...

The California Institute for Regenerative Medicine has funded Keck School of Medicine of USC translational research advancing ...

The 5th Dry AMD and GA Therapeutics Summit will unite 80+ biopharma stakeholders, from discovery to early clinical development, across three days of focused discussion. This summit is the definitive ...

The California Institute for Regenerative Medicine (CIRM), the state's stem cell agency, has awarded a two-year, $6 million ...

Most folks with macular degeneration will have the dry type for their whole life. This form of AMD affects your vision slowly over time. But around 10%-15% of people with dry AMD will get wet AMD ...

The US Food and Drug Administration (FDA) has granted marketing authorisation for LumiThera’s Valeda Light Delivery System to treat dry age-related macular degeneration (AMD). Valeda is said to ...

The Valeda therapy is the first ever authorized treatment by the FDA for vision loss in dry AMD patients. Valeda provides an improvement in best corrected visual acuity (BCVA) over 24 months of >5 ...